Figure S4.
SHM frequency for PCs according to specificity, disease status, V-gene usage, isotype, and longevity. SHM load in the V-region of BCR sequences reconstructed by BraCeR was calculated with IMGT/HighV-QUEST and normalized by sequence length. Average SHM frequencies for heavy and light chain are shown, unless only one of the chains was reconstructed or otherwise stated. P values were calculated with an unpaired Wilcoxon rank-sum test in all subfigures. Adjusted P values are shown. *, P < 0.05; **, P < 0.01; ****, P < 0.0001; ns, nonsignificant. (A) SHM frequency in all BCR sequences from PCs of unknown specificity pooled together according to disease status (UCeD patients n = 4, TCeD patients n = 3, and controls n = 5). (B) Heavy chain (IgH) SHM frequency of DGP-specific PCs and PCs of unknown specificity from patients for which DGP-specific PCs were sorted (n = 4), stratified by usage of the three stereotypical IGHV genes used by DGP-specific PCs. IGHV3-23 and IGHV3-23D are collectively referred to as IGHV3-23(D). (C) SHM frequency of pooled BCR sequences from all CeD patients (n = 7), stratified by specificity and isotype sub(class). (D) SHM frequency of pooled BCR sequences from all controls (n = 5), stratified by isotype (sub)class and PC longevity: short- (CD19+CD45+), intermediate (Int)- (CD19−CD45+), or long lived (CD19−CD45−).

SHM frequency for PCs according to specificity, disease status, V-gene usage, isotype, and longevity. SHM load in the V-region of BCR sequences reconstructed by BraCeR was calculated with IMGT/HighV-QUEST and normalized by sequence length. Average SHM frequencies for heavy and light chain are shown, unless only one of the chains was reconstructed or otherwise stated. P values were calculated with an unpaired Wilcoxon rank-sum test in all subfigures. Adjusted P values are shown. *, P < 0.05; **, P < 0.01; ****, P < 0.0001; ns, nonsignificant. (A) SHM frequency in all BCR sequences from PCs of unknown specificity pooled together according to disease status (UCeD patients n = 4, TCeD patients n = 3, and controls n = 5). (B) Heavy chain (IgH) SHM frequency of DGP-specific PCs and PCs of unknown specificity from patients for which DGP-specific PCs were sorted (n = 4), stratified by usage of the three stereotypical IGHV genes used by DGP-specific PCs. IGHV3-23 and IGHV3-23D are collectively referred to as IGHV3-23(D). (C) SHM frequency of pooled BCR sequences from all CeD patients (n = 7), stratified by specificity and isotype sub(class). (D) SHM frequency of pooled BCR sequences from all controls (n = 5), stratified by isotype (sub)class and PC longevity: short- (CD19+CD45+), intermediate (Int)- (CD19−CD45+), or long lived (CD19−CD45−).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal